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Verification of Current Risk Scores for Kawasaki Disease in 
Korean Children
The purpose of this study was to evaluate and assess the compatibility of current risk 
scoring systems from Japan that were developed to predict intravenous immunoglobulin 
(IVIG) resistance in patients with Kawasaki disease (KD). The authors previously investigated 
another prediction model for patients with refractory KD in Korea. A retrospective study 
involving 350 patients with KD who were admitted between January 2014 and December 
2015 was performed.  Patients younger than 2 years were excluded for the propensity score 
matching in this study. Patients were classified into IVIG responders and IVIG resistance 
groups. The well-known Harada, Kobayashi, and Egami risk scores were calculated for each 
patient, and the proportion of high-risk patients was compared between the two groups 
for each risk score. Logistic regression analysis revealed that platelets, C-reactive protein 
(CRP) levels, and aspartate aminotransferase levels were independent predictors of IVIG 
resistance. Multivariate analysis suggested that platelets and CRP were risk factors. Risk-
scoring systems from Japan have good specificity but low sensitivity. Among the three risk 
scoring systems, the Kobayashi risk score demonstrated significant differences between the 
IVIG resistance and IVIG responder groups in Korean patients with KD. It is very important 
to identify IVIG-resistant patients to protect them from ongoing coronary arterial lesion(s); 
therefore, early prediction and timely optimal additional treatment is of significant benefit. 
It would be helpful to construct a highly sensitive, exclusive scoring system for Korean 
patients with KD.
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INTRODUCTION
Kawasaki disease (KD) is an acute systemic vasculitis of unknown 
etiology that involves small- and medium-size arteries (1). The 
classic diagnostic criteria for KD include 5 days of fever, and at 
least 4 of 5 clinical features, including non-exudative bilateral 
conjunctival injection; erythema of the lips and oral cavity; atyp-
ical rash; edema or erythema of hands, and feet; and cervical 
lymphadenopathy (2). In the recently revised guidelines from 
the Joint Working Group in 2014, at least 5 of 6 items should be 
satisfied for diagnosis of KD. However, patients with 4 items of 
the principal symptoms can be diagnosed with KD when coro-
nary aneurysm or dilation is recognized using two-dimensional 
echocardiography or coronary angiography (3). Patients with 
four or fewer principal symptoms indicative of KD are diagnosed 
with incomplete KD (4).
 Prompt treatment with high-dose (2 g/kg) intravenous immu-
noglobulin (IVIG) and oral acetylsalicylic acid has been shown 
to resolve manifestations of KD, and to significantly decrease 
the prevalence of coronary artery abnormalities. However, most 
studies have indicated that 10% to 15% of patients with KD ex-
perience persistent or recurrent fever after completion of initial 
IVIG administration, indicating treatment resistance (5). Chil-
dren with IVIG resistance are at higher risk for development of 
coronary artery aneurysms. Recent research has focused on 
identification of predictors of IVIG resistance to implement ad-
ditional therapies early in the course of illness and prevent cor-
onary lesions.
 Several different risk scores are used to predict IVIG resistance 
in Japanese children with KD. We chose the Harada, Kobayashi, 
and Egami risk scores (6-8) (Table 1), which are most common-
ly used in clinical practices in Japan, and assessed their perfor-
mance in Korean patients with KD. In the previous studies, there 
have been several trials to compare usefulness of Japanese scor-
ing system for Korean children with KD (9,10). The purpose of 
this study was to investigate clinical risk factors to identify re-
fractory KD, which is appropriate for Korean children.
MATERIALS AND METHODS
Patients and data collection
The patients with KD at Gangnam Severance Hospital (Seoul, 
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Korea), between January 2014 and December 2015 were enrolled. 
Retrospective review of clinical records was performed with lab-
oratory data regarding admission, age, sex, duration of fever (in 
days) at diagnosis, and the results of echocardiography were 
obtained.
 During the study period, 6,633 patients were admitted to our 
pediatric department, and 350 of them (5.28%) were diagnosed 
with KD. KD patients were divided into IVIG responders (n = 245) 
and IVIG resistance (n = 105) groups. IVIG resistant patients re-
quired a second dosage of IVIG or steroid therapy because of a 
persistent or reappearance of fever within 36 hours after the ini-
tial IVIG treatment.
 Single high-dose IVIG (2 g/kg) infused over approximately 
12–24 hours to all the patients. If aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT) were both within 
the reference ranges or only mildly elevated, the medium-dose 
aspirin (30 mg/kg/day) was administered. When body temper-
ature presented below 37.8°C with symptomatic improvement, 
the low-dose aspirin therapy (5 mg/kg/day) started. IVIG-resis-
tant patients received additional IVIG (2 g/kg) or methylpred-
nisolone (30 mg/kg/day) as the second-line therapy.
Echocardiography
Two-dimensional echocardiography was performed at the time 
of diagnosis and repeated approximately 6–8 weeks after diag-
nosis by a pediatric cardiologist. Dimensions of the proximal 
left main coronary artery, proximal left anterior descending cor-
onary artery, and proximal right coronary artery were adjusted 
for body surface area and presented as Z-scores based on a for-
mula reported by Haycock et al. (11). Coronary dilatation was 
defined as a Z-score > 2.5 (12).
Statistical analysis
SAS version 9.4 (SAS Inc., Cary, NC, USA) and R version 3.3.0 
(The R Foundation for Statistical Computing, Vienna, Austria) 
were used for statistical calculations. Data were expressed as 
the mean ± standard deviation for continuous variables, and 
median with range or count with percentage, as appropriate, 
for categorical variables. Propensity score matching was per-
formed for the variable of age at diagnosis because it has a sta-
tistically significant difference between IVIG resistant and IVIG-
responsive children. Student’s t-test and Mann-Whitney U tests 
were used to compare groups, and the χ2 test was applied to 
categorical data; P < 0.05 was considered to be statistically sig-
nificant. To identify independent predictors of IVIG resistance, 
multivariate logistic regression models were constructed using 
variables selected by univariate analysis. Continuous variables 
were converted to dichotomous variables according to the up-
per or lower quartile for each independent predictor identified 
by the multivariate logistic regression. Area under the receiver 
operating characteristic (ROC) curves was calculated to evalu-
ate the capacity of the model. To identify personal risk probabil-
ity that would be used in the nomogram, similar univariate and 
multivariate logistic analyses were performed using variables to 
derive a final variable formula.
Ethics statement
The present study protocol was reviewed and approved by the 
Institutional Review Board of Yonsei University College of Med-
icine (No. 2017-0099-001). Informed consent was submitted by 
all subjects when they were enrolled.
RESULTS
Study subjects include a total of 350 KD patients, consisting of 
200 typical KD patients (57.1%) and 150 incomplete KD pati-
ents (42.9%). The number of patients with resistance was 105 
(30%) and the remaining 245 were responders. Of the 105 resis-
tant patients, 46 (43.8%) patients were incomplete KD, whereas 
of the 245 responder patients, 104 (42.4%) patients were incom-
plete KD. There was statistically significant difference in vari-
able of age. Finally, we performed propensity score matching of 
102 patients in the present study (Fig. 1).
 The baseline characteristics of each group are summarized 
in Table 1. Age ranged from 23 to 53 months (median 38.5 months) 
in the IVIG-responder group, and from 23 to 51 months (medi-
an 39 months) in the IVIG-resistance group, which showed no 
statistical difference (P = 0.909). The total duration of fever was 
2 to 17 days (mean 5.3 days) for the responder group, and 1 to 
10 days (mean 5.1 days) for the resistant group. The one-day fe-
ver patient had BCG site injection, strawberry tongue, and cor-
onary ectasia, so we diagnosed atypical Kawasaki and treated 
IVIG. There were no significant differences in duration of fever, 
sex, and incidence of recurrent KD.
 Regarding laboratory parameters, IVIG-resistant individuals 
were found to have lower platelet levels and higher levels of C-
reactive protein (CRP) and AST; these differences were statisti-
cally significant (Table 2). There were no other statistically sig-
Table 1. Baseline characteristics
Variables
IVIG
P value
Responder (n = 102) Resistance (n = 102)
Age, mon 38.5 (23.0–53.0) 39.0 (23.0–51.0) 0.909
Fever*, day 5.0 (3.0–7.0) 5.0 (3.0–5.0) 0.085
Sex 0.782
   Male 60 (58.8) 58 (56.9)
   Female 42 (41.2) 44 (43.1)
Recurrent 0.847
   No 86 (84.3) 87 (85.3)
   Yes 16 (15.7) 15 (14.7)
Values are presented as median (range) or number (%).
IVIG = intravenous immunoglobulin.
*Febrile days before initial dose of IVIG treatment.
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Table 2. Comparison of laboratory variables
Variables
IVIG
P value
Responder (n = 102) Resistance (n = 102)
White blood cells, 103/μL 10,365.0 (7,410.0–14,910.0) 9,195.0 (6,380.0–14,660.0) 0.606
Neutrophils, % 58.0 (41.4–70.5) 63.1 (47.0–73.7) 0.071
Neutrophils, 103/μL 6,231.5 (3,250.0–9,100.0) 5,330.0 (3,120.0–9,730.0) 0.518
Lymphocytes, 103/μL 2,710.0 (1,860.0–4,290.0) 2,415.0 (1,670.0–3,780.0) 0.072
Neutrophil lymphocyte ratio 1.8 (0.9–3.9) 2.2 (1.2–4.1) 0.238
Hemoglobin, mg/dL 11.8 (11.1–12.4) 11.9 (11.1–12.4) 0.870
Hematocrit, % 34.7 ± 2.5 34.7 ± 2.7 0.990
Platelets, 103/μL 317.5 (254.0–419.0) 267.5 (226.0–345.0) 0.015
ESR, mm/h 48.0 (25.0–67.0) 49.5 (27.0–69.0) 0.957
CRP, mg/dL 21.9 (5.6–60.4) 34.7 (11.5–95.6) 0.019
Na, mmol/L 136.0 (134.0–137.0) 135.0 (133.0–136.0) 0.077
K, mmol/L 4.2 (4.0–4.5) 4.1 (3.9–4.4) 0.607
Ca, mg/dL 9.2 ± 0.5 9.1 ± 0.5 0.308
P, mg/dL 4.4 ± 0.7 4.2 ± 0.8 0.141
Albumin, g/dL 4.1 (3.8–4.2) 4.0 (3.8–4.3) 0.543
SGOT (AST), IU/L 34.5 (27.0–50.0) 38.0 (31.0–67.0) 0.035
SGPT (ALT), IU/L 15.5 (12.0–24.0) 17.5 (13.0–43.0) 0.062
Creatine kinase, U/L 95.0 (61.0–180.0) 85.5 (54.0–160.0) 0.371
CK-MB, mcg/L 2.0 (1.2–3.3) 1.8 (1.1–3.2) 0.505
Total bilirubin, mg/dL 0.3 (0.3–0.4) 0.4 (0.3–0.5) 0.144
Cholesterol, mg/dL 143.2 ± 23.4 138.4 ± 27.6 0.229
Lactate dehydrogenase, IU/L 590.5 (508.0–736.0) 615.5 (517.0–738.0) 0.279
BNP, pg/mL 44.9 (21.1–100.0) 58.3 (26.0–125.2) 0.094
Troponin-T, mcg/L 0.000 (0.000–0.005) 0.000 (0.000–0.005) 0.594
Baseline echo Z-score 0.451
   Z-score (LMCA) 2.6 (2.0–3.2) 2.6 (2.1–3.2) 0.101
   Z-score (LAD) 0.7 (0.3–1.2) 0.9 (0.5–1.4) 0.072
   Z-score (RCA) 0.7 (0.3–1.2) 0.9 (0.4–1.6) 0.222
LVEF, % 66.4 (63.4–70.0) 65.6 (63.1–69.0) 0.062
Data presented as median (range) or mean ± standard deviation, unless otherwise indicated. Bolded values indicate statistically significant differences. 
IVIG = intravenous immunoglobulin, ESR = erythrocyte sedimentation rate, CRP = C-reactive protein, SGOT = serum glutamic oxaloacetic transaminase, AST = aspartate ami-
notransferase, SGPT = serum glutamic pyruvic transaminase, ALT = alanine aminotransferase, CK-MB = creatine kinase myocardial b fraction, BNP = brain natriuretic peptide, 
LMCA = left main coronary artery, LAD = left anterior descending coronary artery, RCA = right coronary artery, LVEF = left ventricular ejection fraction.
Fig. 1. Jitter plots: comparison for age matching.
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nificant differences in indicators between the two groups.
 The Harada, Kobayashi, and Egami scoring systems were ap-
plied to the patients in this study, and the proportion of high-
risk patients identified with each of the three risk scores were 
compared (Table 3). Among the three risk scores, Kobayashi 
showed significant differences between the IVIG-responder 
and IVIG-resistant groups (P = 0.014).
 The sensitivity, specificity, positive predictive value (PPV), 
and negative predictive value (NPV) for each risk score system 
is shown in Table 4. The sensitivity of each scoring system was 
low (31.4%, 31.4%, and 23.5%, respectively) and the specificity 
was high (73.5%, 83.3%, and 87.3%, respectively). Risk scoring 
systems from Japan typically have good specificity but low sen-
sitivity for predicting IVIG resistance in Korean KD patients.
 In multivariate analysis, platelet counts and CRP levels were 
selected as independent predictors of IVIG-resistant KD (Table 
5). The cut-off values, which were identified by the ROC curve, 
were applied in a stepwise procedure (Fig. 2).
 From the result, a nomogram was derived for personal risk 
probability of IVIG resistance in KD patients (Fig. 3). The under-
lying logistic model is given by the equation:
 Probability =  0.5765 + (0.0606) × sex + (−0.0062) × age + 
(−1.0653) × platelets + (1.5756) × CRP
 From this, probabilities for age, sex, platelets, and CRP vari-
Table 3. Comparison of scoring systems
Scoring systems
IVIG
P valueResponder 
(n = 102)
Resistance 
(n = 102)
Harada score 0.466
   Low risk 75 (73.5) 70 (68.6)
   High risk 27 (26.5) 32 (31.4)
Kobayashi score 0.014
   Low risk 85 (83.3) 70 (68.6)
   High risk 17 (16.7) 32 (31.4)
Egami score 0.063
   Low risk 89 (87.3) 78 (76.5)
   High risk 13 (12.8) 24 (23.5)
Data presented as number (%). Bolded value indicates statistically significant differ-
ence.
IVIG = intravenous immunoglobulin.
Table 4. Diagnostic performance
Risk scores Sensitivity Specificity PPV NPV Accuracy
Harada 31.4 (23.2–40.9) 73.5 (64.2–81.2) 54.2 (41.7–66.3) 51.7 (43.7–59.7) 52.5 (45.6–59.3)
Kobayashi 31.4 (23.2–40.9) 83.3 (74.8–89.4) 65.3 (51.3–77.1) 54.8 (47.0–62.5) 57.4 (50.6–64.1)
Egami 23.5 (16.3–32.7) 87.3 (79.3–92.5) 64.9 (48.7–78.2) 53.3 (45.7–60.7) 55.4 (48.6–62.2)
Data presented as percentage (range).
PPV = positive predict value, NPV = negative predict value.
Table 5. Multiple conditional logistic regression analysis
Risk factors OR 95% CI P value
Platelets 278 × 103/μL 0.997 0.994–0.999 0.012
CRP 111.4 mg/dL 1.008 1.001–1.014 0.016
OR = odds ratio, CI = confidence interval, CRP = C-reactive protein.
Fig. 2. ROC curve and area under the curve comparison.
ROC = receiver operating characteristic.
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ables can be estimated.
 For example, if a 100-month-old female KD patient with a 
platelet count of 250,000/μL and CRP level of 120 mg/dL, female 
is linked to sex 2 and converted to 5 points and 100 months would 
be altered to 12.5 points. Moreover, platelets would be convert-
ed into 67.5 points, and CRP was given 100 points. The total point 
axis in Fig. 3 can reach a maximum of 185 points, with a predict-
ed probability range of approximately 0.84.
DISCUSSION
In Japan, Harada (6), Kobayashi et al. (7), and Egami et al. (8) 
proposed scoring systems for predicting IVIG non-responders 
using various parameters, which is well matched in Japanese 
patients with complete KD. However, in a previous study, Sleep-
er et al. (13) concluded that these Japanese scoring systems were 
not suitable for the North American population. A random co-
hort study in a United States population found a sensitivity of 
42% and a specificity of 85% for the Egami score, and a sensitiv-
ity of 42% and specificity of 87% for the Kobayashi score. Davies 
et al. (14) used the Kobayashi scoring system for children with 
KD from the United Kingdom, and found a sensitivity of 58% 
and a specificity of 35%. These results indicate that the Kobayas-
hi scoring system is not useful in the British population. Fu et 
al. (15) predicted IVIG resistance in Chinese children with KD, 
and found a sensitivity of 21% and specificity of 87% for Egami 
scores, and a sensitivity of 49% and sensitivity of 72% for the Ko-
bayashi score. Based on these findings, Japanese KD scoring 
systems were considered to have limited predictive value for 
IVIG response in other countries. Korea is home to the second 
largest KD population in the world; therefore, we have evaluat-
ed whether these scoring systems would be suitable there.
 According to a recent nationwide survey in Korea in 2011, the 
11.6% of patients did not respond to initial IVIG treatment and 
coronary artery dilation was noted in 16.4% of patients, based 
on the Japanese Ministry of Health and Welfare criteria (16). De-
spite the timely administration of IVIG, 10% to 20% of patients 
do not respond to treatment. These refractory patients are at in-
creased risk of developing coronary artery complications. It is 
very important to identify high-risk patients for protecting against 
ongoing coronary arteriopathy. The significance of coronary 
outcomes emphasizes the importance of early prediction and 
timely optimal additional treatment of IVIG-resistant patients.
 Previous studies have reported risk factors for refractory KD, 
which include high neutrophil count; low hemoglobin; throm-
bocytopenia; low albumin; high CRP; high lactate dehydroge-
nase; hyponatremia; elevated AST; abnormal findings in initial 
echocardiography; and recurrent KD (17-19). Most risk factors 
are related to severe inflammatory reactions and are not sup-
pressed by IVIG alone. In IVIG-resistance, fever represents on-
going inflammatory reactions in vessels and may reflect defects 
in the control of immunological stimuli (20).
 Previous reports to predict IVIG resistance KD have mostly 
excluded incomplete KD. However, our study included patients 
with high rates of incomplete KD. This may have been a factor 
in determining whether previous studies were appropriate for 
our patients.
 Our study tested the utility of current risk scores in Korean 
patients with KD. They have good specificity but low sensitivity 
for predicting IVIG resistance. The scoring system suggested by 
Kobayashi et al. (7) can help predict IVIG-resistant KD and lead 
to timely management and better clinical outcomes. In addi-
tion, from the results of our study, we identified a few indepen-
dent predictive parameters for refractory KD — platelets and 
CRP level — that suggest a more focused importance of vascu-
lar inflammatory reactions in the disease process.
 This study had some limitations, the first of which was its ret-
rospective, single-center design; consequently, we could not 
obtain sufficient data regarding clinical characteristics and lab-
oratory findings. Second, many patients were excluded because 
of a lack of adequate data or results in age matching. The inci-
dence of coronary complications is highly reported in extreme 
age group, but in our study, there is a limit due to age matching. 
Third, we could not exclude patients with comorbidities from 
other febrile illnesses.
 In conclusion, Korean KD patients may need an exclusive 
scoring system. The result of our study may be helpful in select-
ing patients who are at high-risk for IVIG resistance or coronary 
artery complications. Further multicenter studies are needed to 
develop a better and more comprehensive evaluation system to 
provide individualized treatment planning.
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